The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter phase II study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.
 
Kosei Hasegawa
Honoraria - Chugai Pharma; Ono Pharmaceutical
Consulting or Advisory Role - ImmunoGen
 
Muneaki Shimada
No Relationships to Disclose
 
Satoshi Takeuchi
No Relationships to Disclose
 
Hiroyuki Fujiwara
No Relationships to Disclose
 
Yuichi Imai
No Relationships to Disclose
 
Norihiro Iwasa
No Relationships to Disclose
 
Satoru Wada
No Relationships to Disclose
 
Hidetaka Eguchi
No Relationships to Disclose
 
Tetsuro Oishi
No Relationships to Disclose
 
Toru Sugiyama
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo
Speakers' Bureau - Chugai Pharma
Research Funding - Daiichi Sankyo
 
Mitsuaki Suzuki
No Relationships to Disclose
 
Masahiko Nishiyama
Research Funding - Yakult Honsha
 
Keiichi Fujiwara
Honoraria - Chugai Pharma; Eisai; Kyowa Hakko Kirin; Nippon Kayaku; Taiho Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; MSD; Pfizer
Research Funding - Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Pfizer